Alloy Therapeutics raises $40m Series E at $1bn valuation
The financing supports new discovery technologies, later-stage development services and AI integration across Alloy Therapeutics’ infrastructure.
Scaling a shared drug-development platform
Alloy Therapeutics announced a $40 million Series E on April 15, 2026, at a $1 billion valuation. Investors included 8VC, JIC Venture Growth Investments, Echo Capital and existing backers including Mubadala Capital, Presight and Founders Fund.
The company identified three uses for the financing: expanding discovery technologies, strengthening downstream preclinical and clinical services, and integrating AI and data across its platforms. At the announcement, Alloy reported more than 200 partners and 100 licensed programs, including 22 in clinical development and two in Phase 3. Those figures describe the financing announcement’s operating context.